Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Brunner, Thomas
RADIANCE, NCT04230759 / 2018-003005-25: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group	Active, not recruiting	2	180	Europe	Chemotherapy, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Mitomycin C (MMC) are allowed, Radiation, Durvalumab, PD-L1 inhibitor	Goethe University, German Cancer Aid, AstraZeneca	Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II	12/26	03/27
NCT06411392: SBRT for Ventricular Arrhythmia	Recruiting	N/A	10	Europe	Stereotactic Antiarrhythmic Radiotherapy	Medical University of Graz	Ventricular Arrythmia	02/27	02/27